Table 2.
Clinical characteristics of MDS patients
| Features | |
|---|---|
| No. of patients | 80 |
| Sex, M/F | 41/39 |
| Age(years), median (range) | 53 (24-82) |
| WBC (109/L), median (range) | 3.5 (0.5-15.9) |
| Neutrophils(109/L), median (range) | 0.9 (0-8.1) |
| Hemoglobin (g/L), median (range) | 68 (40-153) |
| RBC (1012/L), median (range) | 2.7 (3.1-5.6) |
| Platelets (109/L), median (range) | 64 (5-571) |
| MCV (fL), median (range) | 101 (70-125) |
| WHO subgroups | |
| MDS-SLD | 14(17.5%) |
| MDS-MLD | 32 (40.0%) |
| MDS-U | 11(13.8%) |
| MDS-EB-I | 12 (15.0%) |
| MDS-EB-II | 11 (13.8%) |
| IPSS-R risk groups | |
| Very Low | 12(15.0%) |
| Low | 35 (43.7%) |
| Intermediate | 13 (16.3%) |
| High | 12 (15.0%) |
| Very High | 8 (10.0%) |
WBC: white blood cells; RBC: red blood cell; MCV: mean corpuscular volume; MDS-SLD: MDS with single lineage dysplasia; MDS-MLD: MDS with multilineage dysplasia; MDS-U: MDS-unclassifiable; MDS-EB-1: MDS with excess blasts-1; MDS-EB-2: MDS with excess blasts- 2; IPSS-R: Revised-International Prognostic Scoring System.